AI Consensus Investment Thesis
TDOC: Teladoc Health Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Teladoc Health: 1-Year and 5-Year Forecast Outlook and Rating
Teladoc Health (TDOC) has an immediate Strong Buy & Keep consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $7.58 for , with +22.06% expected return (+22.06% including net dividends) and a STRONG BUY rating.
The 5-year target is $12.76 for , with +105.48% expected return (+105.48% including net dividends) and a BUY rating.
Latest available market price: USD 6.21, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Teladoc Health Flagship Insight
Virtual Care Pioneer Navigates Looming Convertible Debt Wall Amid Chronic Margin Inflection
Analyses reveal sharp divergence regarding normalized free cash flow durability, yet high consensus that core enterprise integrated care provides essential operational ballast. While direct-to-consumer therapy suffers ongoing attrition, substantial balance-sheet liquidity and expanding commercial payer reimbursements buffer upcoming convertible debt maturities against immediate insolvency risks.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
J.P. Morgan (Titan)
Universal Investor (Polymath)
Warren Buffett (Value Purist)
Michael Burry (Vulture)
Machiavelli (Insider)
Ray Dalio (Strategist)
Superintelligence (Anthropologist)
Elon Musk (Visionary)
Sherlock Holmes (Whistleblower)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Teladoc Health: forecast questions
What is Teladoc Health (TDOC)'s 1-year price forecast?
Teladoc Health's 1-year target is $7.58 for Sept 2027. The current AI rating is STRONG BUY. The expected return from the recorded close is +22.06%, or +22.06% modeled return including net dividends. Latest available market price: USD 6.21, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Teladoc Health (TDOC)'s 5-year price forecast?
Teladoc Health's 5-year target is $12.76 for Sept 2031. The current AI rating is BUY. The expected return from the recorded close is +105.48%, or +105.48% modeled return including net dividends. Latest available market price: USD 6.21, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 6.21, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Teladoc Health forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Teladoc Health differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Teladoc Health is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Teladoc Health: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Teladoc Health at the latest market close (20 Oct 2026): $20,548 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
The investment thesis centers on an acute mispricing between perceived insolvency and durable enterprise cash generation. While direct-to-consumer therapy revenue contracts under marketing cost inflation, the B2B Integrated Care segment delivers an entrenched, high-margin subscription annuity across one hundred million covered lives. Forensic accounting reveals that headline free cash flow is flattered by software capitalization; normalized cash generation is approximately $120 million to $140 million rather than the headline $225 million. Nevertheless, existing liquidity and positive operational cash flow fully cover the June 2027 convertible maturity without requiring dilutive equity recapitalization. Valuation sensitivity remains tied to refinancing costs and consumer stabilization.
Key insights
- Capitalized software accounts for over ninety percent of capital expenditures, requiring investors to evaluate normalized cash conversion rather than flattering headline yields.
- Transitioning consumer therapy toward contracted commercial insurance expands patient addressability but introduces clinician credentialing bottlenecks and bureaucratic payer revenue collection delays.
- Resolving the convertible maturity removes binary distress discounts, yet higher replacement borrowing coupons permanently reduce net margins and per-share compounding velocity.
Teladoc Health: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 6.21, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 6.3. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $6.33 | +0.53% | +1.93% | +1.93% | Third-quarter results reflect persistent consumer therapy contraction and seasonal digital ad inflation. Year-end tax-loss selling and looming convertible debt maturities keep sentiment depressed, though positive underlying operating cash flow prevents further structural breakdown. | $5.80 | $6.80 | $750 | |
| $6.66 | +5.12% | +7.25% | +7.25% | Full-year reporting and forward guidance clarify the commercial insurance transition at BetterHelp. Management outlines an executable framework utilizing liquid cash reserves to address upcoming convertible debt, initiating modest multiple stabilization from distressed levels. | $5.45 | $8.03 | $736 | |
| $7.21 | +8.26% | +16.10% | +16.10% | The June convertible maturity dominates market dynamics. Cash settlement and modest replacement credit lines neutralize immediate solvency risk without common equity dilution, triggering sharp institutional short-covering despite temporary liquidity drawdowns. | $5.61 | $9.23 | $743 | |
| $7.58 | +5.11% | +22.06% | +22.06% | Post-refinancing clarity establishes a renewed fundamental baseline. Higher interest expense on replacement debt tempers enthusiasm, but expanding chronic care enrollment and initial commercial insurance reimbursement gains support sequential operational stabilization. | $5.95 | $10.16 | $755 | |
| $7.96 | +5.12% | +28.18% | +28.18% | Autumn employer health plan selling season confirms solid enterprise retention across Fortune 500 accounts. Narrowing net losses and reduced stock-based compensation demonstrate sustained overhead discipline, supporting gradual multiple recovery into year-end. | $6.19 | $10.97 | $776 | |
| $8.37 | +5.05% | +34.78% | +34.78% | Full-year 2027 financials demonstrate adjusted EBITDA resilience and positive post-software free cash flow. As solvency fears recede permanently, fundamental value investors re-rate the business toward historical healthcare IT utility multiples. | $6.50 | $11.63 | $787 | |
| $8.77 | +4.79% | +41.22% | +41.22% | BetterHelp commercial insurance sessions scale, partially offsetting legacy cash-pay attrition. Ambient clinical documentation tools lower provider administrative burdens, expanding gross margins toward seventy percent and confirming operational turnaround feasibility. | $6.69 | $12.44 | $803 | |
| $8.92 | +1.78% | +43.64% | +43.64% | Mid-year consultation seasonality and competitive pricing pressure from captive payer telehealth networks moderate top-line momentum. Underlying cash generation remains steady, allowing the balance sheet to absorb modest working-capital fluctuations without strain. | $6.57 | $13.06 | $812 | |
| $9.31 | +4.33% | +49.92% | +49.92% | Enterprise contract renewals show healthy uptake of bundled cardiometabolic and weight-management programs. Disciplined capital allocation and growing cash reserves support equity valuation, offsetting continued low-single-digit top-line drag in consumer mental health. | $6.90 | $13.85 | $839 | |
| $9.69 | +4.05% | +56.04% | +56.04% | Full-year 2028 results mark an inflection toward GAAP operating breakeven as historical acquisition amortization drops off the income statement. Eliminating accounting deficits attracts quantitative institutional screens, driving steady equity accumulation. | $7.18 | $14.40 | $851 | |
| $10.04 | +3.63% | +61.67% | +61.67% | Commercial insurance integration at BetterHelp matures, establishing predictable recurring session gross profits. Voluntary early term debt paydowns reduce annual interest burdens, directly lifting per-share cash generation and de-risking the capital structure. | $7.46 | $15.12 | $872 | |
| $10.31 | +2.70% | +66.02% | +66.02% | Summer seasonal consultation lulls prompt minor consolidation. However, entrenched provider integration across regional health plans defends high-margin recurring access fees, insulating the equity from broader macroeconomic and healthcare tech volatility. | $7.68 | $15.57 | $886 | |
| $10.67 | +3.47% | +71.82% | +71.82% | Favorable open-enrollment additions across self-insured corporate accounts deliver strong top-line visibility for the upcoming fiscal year. Expanding adjusted EBITDA margins reflect cumulative administrative efficiencies, underpinning consistent quarterly share appreciation. | $7.83 | $16.20 | $910 | |
| $11.00 | +3.12% | +77.13% | +77.13% | Full-year 2029 disclosures confirm sustained positive GAAP net income and robust free cash flow. Management evaluates shareholder-friendly capital return strategies, cementing market recognition of the company as an essential digital healthcare utility. | $7.99 | $16.85 | $916 | |
| $11.20 | +1.85% | +80.35% | +80.35% | Automated clinical triage and AI-assisted provider workflows further compress delivery overhead per consultation. Operating leverage strengthens across Integrated Care, cushioning the platform against ongoing visit-based pricing concessions demanded by national payers. | $7.83 | $17.35 | $937 | |
| $11.45 | +2.24% | +84.38% | +84.38% | Predictable operational execution across enterprise and behavioral segments maintains steady quarterly cash conversion. The equity trades in an orderly valuation channel, supported by mid-single-digit free cash flow compounding and pristine liquidity. | $8.14 | $17.87 | $947 | |
| $11.85 | +3.51% | +90.82% | +90.82% | Year-end balance-sheet deleveraging leaves net cash in a robust surplus position. Stable chronic care subscriber retention balances mature direct-to-consumer therapy dynamics, providing dependable price support during annual portfolio rebalancing cycles. | $8.46 | $18.85 | $970 | |
| $12.19 | +2.84% | +96.30% | +96.30% | Full-year 2030 earnings highlight clean operational profitability and negligible credit risk. Sell-side analysts upgrade coverage models to reflect a durable cash cow rather than a distressed speculative turnaround, sustaining upward momentum. | $8.56 | $19.79 | $980 | |
| $12.47 | +2.34% | +100.81% | +100.81% | Mature-phase execution delivers predictable clinical encounter volumes across commercial and Medicare Advantage accounts. Modest payer pricing scrutiny is fully offset by overhead discipline, maintaining stable operating margins and consistent cash flow. | $8.30 | $20.6 | $1,000 | |
| $12.76 | +2.25% | +105.48% | +105.48% | The five-year transformation concludes with the business valued as an indispensable, cash-generative healthcare software utility. Re-rated valuation multiples and accumulated balance-sheet cash deliver substantial cumulative recovery from trough entry levels. | $8.47 | $21.2 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Teladoc Health Stock Analysis & Scenarios Deep Dive
Teladoc Health: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Market consensus has dismissed the enterprise as an irrecoverable pandemic relic, anchored to historical goodwill write-downs and relentless revenue decay in consumer mental health. Investors widely assume that high customer acquisition costs are fatal, treating the 2027 convertible debt wall as an existential solvency threat. Consequently, prevailing sentiment prices the equity at a distressed multiple, convinced that dilutive recapitalization or operational insolvency is inevitable.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value due to an analytical blind spot that conflates consumer therapy headwinds with enterprise insolvency. The market overlooks that Integrated Care delivers resilient adjusted EBITDA margins above sixteen percent across an entrenched B2B base, while $774 million in cash and positive operational cash flow provide sufficient liquidity to retire maturing convertible notes without dilutive equity issuance. However, bulls who cite an unadjusted twenty percent free cash flow yield ignore heavy software capitalization, meaning true intrinsic undervaluation is meaningful but moderate.
Repricing Catalyst
What could make the market recognize and close that gap? The decisive catalyst is the formal resolution of the $996.7 million convertible senior notes due June 1, 2027 through a combination of existing cash reserves and modest credit facilities. Retiring this liability without dilutive equity issuance dispels existential bankruptcy fears, compelling credit markets and institutional investors to re-evaluate the company on normalized cash earnings. The first observable confirmation will emerge via announced refinancing terms or cash tender repurchases during early 2027.
Teladoc Health: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Extreme Fear
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Stabilization
Sentiment converges on severe pessimism regarding direct-to-consumer therapy churn, yet opinions diverge on cycle positioning between late capitulation and early stabilization. The decisive tension centers on whether debt maturity resolution triggers an immediate relief re-rating or a protracted multi-year grind.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of elevated central bank interest rates and restrictive credit conditions is a distinct headwind. High benchmark yields raise prospective borrowing costs when rolling over maturing debt and compress equity valuation multiples. However, corporate employer demand for cost-saving virtual healthcare benefits provides defensive operational insulation against broader macroeconomic deceleration.
Advisor Disagreement
What do our AI Advisors disagree about most? The most consequential analytical debate centers on true normalized cash generation and the ultimate fate of BetterHelp. One camp argues that reported trailing cash flow of $225 million reflects an unassailable twenty percent yield, paving the way for rapid balance-sheet de-leveraging. The opposing view demonstrates that deducting heavy capitalized software development cuts true cash flow near $130 million, while consumer churn will permanently depress top-line revenue. Reconciling this debate requires monitoring second-half 2026 cash conversion after capitalized software, alongside commercial insurance run-rates from the upcoming quarterly filings.
Teladoc Health: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Enterprise Integrated Care contract stability | Competitive Positioning | +32% | +28% | Integrated Care serves over one hundred million members, delivering stable revenues and adjusted EBITDA margins near 16.5%. Entrenched employer relationships and multi-condition cross-selling create substantial switching friction, defending core B2B cash flows against commoditization. This recurring enterprise earnings foundation insulates the business from retail therapy volatility and permanently finances ongoing digital health modernization. |
| Convertible note balance sheet derisking | Capital Allocation | +28% | +15% | Management possesses $774 million in cash alongside an undrawn revolving credit facility to address the $996.7 million convertible debt due June 2027. Retiring this liability through internal liquidity and modest bank facilities eliminates insolvency overhang, dramatically compressing credit default spreads and unlocking substantial equity multiple expansion from distressed historical lows. |
| BetterHelp commercial insurance network pivot | Innovation And Product | +24% | +25% | Transitioning BetterHelp from direct-to-consumer cash subscriptions toward contracted commercial insurance unlocks access to over 150 million covered lives. While initial clinician credentialing creates temporary capacity bottlenecks, in-network reimbursement lowers member acquisition costs, lengthens retention curves, and replaces volatile consumer advertising auctions with durable, recurring payer-sponsored session volume across the five-year horizon. |
| Operational overhead and compensation discipline | Operational Efficiency | +18% | +22% | Executive leadership has aggressively curtailed corporate overhead and trimmed stock-based compensation by over thirty percent year-over-year. Concurrently, deploying automated intake routing and clinical documentation tools reduces clinician visit completion times. This administrative austerity closes the chasm between GAAP net loss and adjusted EBITDA, systematically enhancing operational cash flow conversion over the forecast cycle. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Consumer therapy cash pay attrition | Competitive Positioning | -22% | -24% | BetterHelp faces relentless structural headwinds as inflationary pressures squeeze discretionary household mental health budgets. Paying users fell eleven percent year-over-year as cash-pay subscribers churned, while aggressive digital advertising competition inflated acquisition costs. This persistent consumer fatigue depresses segment revenue, exerting an enduring drag on consolidated earnings until commercial insurance reimbursement achieves critical scale. |
| Replacement debt coupon step up | Macroeconomic And Macrofinancial | -18% | -16% | The 2027 convertible notes carry an ultra-low 1.25% coupon. Refinancing any residual portion in a restrictive monetary regime with policy rates near 4% will require market rates between 7% and 9%. This coupon step-up will add tens of millions in annual cash interest expense, directly compressing net income and constraining discretionary capital reinvestment. |
| Virtual care pricing commoditization pressure | Sector And Industry | -15% | -14% | Basic telehealth consultations face aggressive commoditization from regional hospital health systems, retail pharmacy clinics, and captive payer virtual networks like Optum. Health plan sponsors demand price concessions and shift contracts from fixed per-member subscription fees to utilization-based visit models. This pricing compression limits organic revenue expansion and caps long-term gross margin growth across commercial accounts. |
| Capitalized software free cash flattery | Management And Governance | -12% | -10% | Reported free cash flow is heavily flattered by accounting conventions, as capitalized software development represents over ninety percent of total capital spending. Deducting software additions reduces true trailing cash generation from $225 million toward $130 million. Investors normalizing for recurring development expenditures will adjust cash flow yields downward, dampening potential valuation multiple expansion. |
Teladoc Health: What Could Break or Accelerate the Thesis
Event Risk Score: High 69/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Credit freeze forced equity dilution | 22% | -50% | Dislocations across corporate credit markets coincide with operational cash deterioration ahead of the June 2027 convertible debt maturity. Unable to issue replacement credit facilities on viable terms and lacking sufficient unrestricted liquidity, management is forced into a punitive rescue financing involving deeply discounted equity-linked instruments. This restructuring would heavily dilute existing common shares, permanently crushing per-share value despite existing cash reserves holding probability below half. |
| BetterHelp regulatory and privacy penalties | 20% | -45% | Federal regulators or state attorneys general initiate sweeping enforcement actions over consumer data privacy, tracking pixels, or therapist credentialing compliance across online therapy platforms. Imposed statutory fines, mandated operational curbs, and reputational fallout would collapse user onboarding funnels and prompt commercial insurers to freeze reimbursement partnerships. While comprehensive compliance remediation keeps probability below fifty percent, materialization would decimate behavioral health cash generation and trigger major impairments. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Strategic private equity buyout bid | 28% | +65% | A private equity consortium or commercial payer launches an unsolicited takeover bid, capitalizing on depressed valuations near 0.5 times sales and predictable B2B cash flows. A buyer could carve out BetterHelp and optimize Integrated Care away from public scrutiny. The event remains below fifty percent probability due to antitrust scrutiny, but would command a substantial control premium. |
| Commercial GLP1 companion program breakthrough | 25% | +55% | Commercial payers mandate digital lifestyle and clinical companion programs for reimbursed anti-obesity and cardiometabolic medications starting in 2027. Leveraging its established chronic condition architecture, the enterprise captures preferred vendor status across national employer coalitions. This catalytic alignment injects hundreds of thousands of high-margin subscriptions into Integrated Care, accelerating organic revenue into double digits. Probability remains below fifty percent because payers frequently evaluate internal disease management alternatives. |
Company Financial AnalysisTeladoc Health: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Teladoc Health financials here.
Earnings and financials
Reported financial results present a striking contrast between headline accounting deficits and resilient operational cash production. For fiscal 2025, revenue contracted slightly to $2.53 billion, while reported net losses narrowed dramatically to $200 million as massive historical goodwill write-offs ended. Second-quarter 2026 revenue of $607 million reflected continued contraction in consumer therapy, but enterprise healthcare services held steady. Crucially, headline accounting losses are driven by non-cash amortization from past acquisitions rather than ongoing cash burn. The core business generated $225 million in trailing cash flow, though factoring in internal software spending lowers true underlying cash generation closer to $130 million. This cash cushion stabilizes the company while management reshapes operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 2.5B | USD -200.3M | USD 285.5M |
| 2024 | USD 2.6B | USD -1B | USD 282.9M |
| 2023 | USD 2.6B | USD -220.4M | USD 193.7M |
| 2022 | USD 2.4B | USD -13.7B | USD 172.8M |
| 2021 | USD 2B | USD -428.8M | USD 185.5M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability metrics reveal a dramatic split between operating units. Consolidated gross margins remain structurally high near 70%, proving that core virtual clinical consultations retain attractive underlying economics. However, operating margins diverged sharply in the second quarter of 2026: Integrated Care maintained a solid 16.5% adjusted EBITDA margin, while consumer-focused BetterHelp fell to breakeven at 0.2%. This divergence stems from inflated advertising costs in direct-to-consumer therapy, which management addressed by reducing marketing spend. Shifting therapy into in-network commercial insurance reduces member acquisition costs. As non-cash acquisition amortization rolls off and cost discipline takes hold, consolidated operating profitability is positioned to rebound gradually.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -263M | -10.4% | -7.9% |
| 2024 | USD -1B | -39.7% | -39.0% |
| 2023 | USD -248.6M | -9.6% | -8.5% |
| 2022 | USD -13.2B | -548.4% | -567.5% |
| 2021 | USD -265.6M | -13.1% | -21.1% |
Balance sheet and leverage
The balance sheet presents a sharp contrast between substantial liquid resources and an impending debt maturity. Teladoc held $774 million in cash equivalents at the end of June 2026 against $996.7 million in convertible senior notes maturing in June 2027. An undrawn $300 million credit facility provides total gross liquidity exceeding $1.07 billion. This ample liquidity disproves widespread market fears of imminent bankruptcy. Management has adequate capacity to retire the notes using accumulated cash and conservative bank loans without diluting shareholders. However, repaying the debt will reduce cash balances and raise interest expenses on replacement borrowing, making ongoing operational cash generation essential.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 1B | USD 781.1M | USD 259.1M net debt | USD 259.1M | 2.69x |
| 2024 | USD 1.6B | USD 1.3B | USD 286.3M net debt | USD 286.3M | 1.77x |
| 2023 | USD 1.6B | USD 1.1B | USD 468.6M net debt | USD 468.6M | 3.54x |
| 2022 | USD 1.6B | USD 918.2M | USD 668.7M net debt | USD 668.7M | 3.22x |
| 2021 | USD 1.3B | USD 896M | USD 386.7M net debt | USD 384.1M | 3.70x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Physical capital expenditure appears almost nonexistent, with traditional equipment purchases absorbing only 0.35% of revenue in 2025 and just $2.6 million during the first half of 2026. This reflects a virtual delivery model that requires minimal brick-and-mortar investment compared to physical hospital networks. However, real capital intensity is concentrated in software development, which consumed $62.2 million during the first half of 2026. Management has redirected investment away from aggressive consumer marketing toward platform automation and clinical intelligence tools. This software discipline protects near-term cash reserves ahead of upcoming bond maturities, though continuing technology spending remains essential to prevent platform obsolescence against rivals.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 8.9M | USD 277.9M |
| 2024 | USD 10.8M | USD 307.3M |
| 2023 | USD 156.3M | USD 348.5M |
| 2022 | USD 16.5M | USD 333.6M |
| 2021 | USD 8.5M | USD 311.9M |
Behind the synthesisTeladoc Health: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
Independent assessments converge on a critical operational dichotomy: durable enterprise Integrated Care subscription cash flows contrast with sharp consumer therapy revenue decay. Most perspectives acknowledge that existing balance-sheet liquidity and undrawn credit capacity provide sufficient runway to resolve the impending 2027 convertible debt maturity. However, relative weighting heavily rewards analyses that rigorously adjust free cash flow for aggressive software capitalization and executive stock compensation rather than uncritically accepting headline trailing cash metrics. The strongest contrarian case cautions that higher replacement borrowing coupons in a restrictive monetary regime will permanently compress equity earnings once low-coupon debt matures. Conversely, unverified assumptions regarding imminent bankruptcy or effortless multiple expansion to pre-pandemic peaks are systematically downweighted. Relative allocations prioritize forensic scrutiny of working capital and debt rollover mechanics over speculative takeover narratives.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 16.4%
Weighted highest alongside the primary polymath report for exceptional evidentiary rigor, reconstructing normalized free cash flow by expensing capitalized software, modeling equity dilution, and establishing a grounded, realistic valuation framework.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 16.4%
Receives superior weighting due to forensic examination of software capitalization flattery, realistic normalization of free cash flow, and detailed segmentation between high-margin Integrated Care and deteriorating direct-to-consumer therapy ahead of the critical 2027 debt maturity.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.1%
Merits substantial weighting for rigorous segment EBITDA decomposition, realistic appraisal of commercial insurance transition timelines, and disciplined balance-sheet tracking that demonstrates non-dilutive debt retirement capability from internal liquidity.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.1%
Merits significant allocation for disciplined balance-sheet forensics, accurate appraisal of convertible debt redemption capacity using existing cash, and clear identification of therapist recruitment bottlenecks in behavioral health.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.3%
Supported by solid forensic tracking of commercial in-network coverage expansion, administrative overhead cuts, and executable debt retirement steps, providing strong evidence-based causal links between operational stabilization and multiple recovery.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.3%
Merits high weighting for incisive appraisal of regulatory telehealth extension dynamics, payer insourcing frictions, and detailed mechanics of replacement financing costs in a restrictive central bank monetary regime.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Assigned moderate weight for sound identification of core enterprise switching costs and balance-sheet liquidity, though limited by uncritical reliance on headline trailing cash flow without adjusting for heavy historical capitalized software development outlays.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Receives balanced weighting for valuable analysis of executive payer restructuring and chronic care cross-selling dynamics, but downweighted for overly optimistic multiple expansion assumptions in an elevated interest rate environment.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Weighted moderately for a pragmatic assessment of enterprise healthcare inertia and aggressive overhead pruning, though discounted for treating clinical software commoditization and competitive AI threats with insufficient balance-sheet depth.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Assigned moderate weight for coherent analysis of multi-condition bundling and commercial payer expansion, though constrained by optimistic multiple normalization targets that overlook prospective replacement debt coupon step-ups.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Receives balanced allocation for recognizing the enterprise cash-harvesting turnaround and downside book value protections, tempered by somewhat generic treatments of AI clinical disintermediation and stock-based compensation dilution.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Weighted moderately for robust macroeconomic contextualization and enterprise chronic care stickiness analysis, but tempered by aggressive price-to-sales multiple targets that exceed historical post-bubble medtech reorganization standards.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.5%
Receives balanced weighting for detailed examination of provider credentialing bottlenecks and visit-based contract transitions, balanced against an aggressive projection of terminal valuation multiple recovery that slightly understates long-term competitive payer insourcing.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 2.7%
Assigned lower weight due to substantial reliance on unadjusted headline cash flow figures and repeated debt-buyback assumptions, though credited for recognizing enterprise contract switching costs and short-term liquidity cushions.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Teladoc Health forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web28 available sources from this batch (52 recorded). The first 15 are shown below; expand to read the rest.
- Federal Reserve Board - Federal Reserve issues FOMC statement federalreserve.gov
- 0001477449 false 0001477449 2020-05-18 2020-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares sec.gov
- Sec sec.gov
- tdoc-20251231 sec.gov
- tdoc-20260630 sec.gov
- Teladoc Health, Inc. - Form 10-Q - FY2026 sec.gov
- Teladoc Health, Inc. - Teladoc Health Reports Second Quarter 2026 Results ir.teladochealth.com
- Dealroom.co | BetterHelp president sells entire $71K Teladoc stake, exits position completely app.dealroom.co
- Let's Buy BetterHelp beyondbillions.substack.com
- TDOC Stock Quote Price and Forecast | CNN cnn.com
- Teladoc Health CEO lays out telehealth giant's M&A strategy following first year at the helm fiercehealthcare.com
- Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path? (TDOC) finance.yahoo.com
- Teladoc Health Q2 Earnings Call Highlights finance.yahoo.com
- Teladoc Health, Inc. Q2 2026 Earnings Call Summary finance.yahoo.com
- Teladoc Q2 2026 slides: revenue miss drives sharp stock decline By Investing.com investing.com
Show 13 more sources
- Teladoc Health, Inc. - Investors ir.teladochealth.com
- Teladoc Health, Inc. - Teladoc Health Reports Fourth Quarter and Full Year 2025 Results ir.teladochealth.com
- TDOC - Teladoc Stock Price Quote - NYSE | Morningstar morningstar.com
- Teladoc Health Reports Second Quarter 2026 Results | Nasdaq nasdaq.com
- Teladoc Health: Improving Fundamentals Support A Turnaround Story (NYSE:TDOC) | Seeking Alpha seekingalpha.com
- Teladoc Health (TDOC) Stock Forecast & Analyst Price Targets stockanalysis.com
- Teladoc Health (NYSE: TDOC) Q2 2026 revenue dips as BetterHelp weakens stocktitan.net
- Teladoc Health (NYSE: TDOC) Q2 2026 shows revenue dip and weaker BetterHelp stocktitan.net
- Teladoc Health posts Q1 2026 results | TDOC Quarterly Report (10-Q) stocktitan.net
- BetterHelp Launches “We Believe in Better,” Backed by New Data on Mental Health Outcomes teladochealth.com
- Teladoc Health introduces a virtual care practice built around the person, shaping a new era of connected care teladochealth.com
- Teladoc faces activist shareholder challenge, demanding $200M stock buyback, business spinoffs, cost cuts | Telehealth and Telecare Aware telecareaware.com
- Teladoc Health Inc (TDOC) Balance Sheet - Tradingkey.com tradingkey.com
24 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.